Kodiak Sciences Inc (KOD) is a clinical-stage biopharmaceutical company developing antibody-biopolymer conjugate medicines for retinal diseases. Its programs include tarcocimab and other long-acting therapies for macular degeneration and diabetic eye disease. Its pipeline also includes KSI-501, a bispecific IL-6/VEGF trap, and KSI-101, a high-strength bispecific protein targeting IL-6 and VEGF.